Novacyt - Asset Resilience Ratio
Novacyt (ALNOV) has an Asset Resilience Ratio of 0.02% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Novacyt's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2008–2025)
This chart shows how Novacyt's Asset Resilience Ratio has changed over time. See how leveraged is Novacyt's balance sheet to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Novacyt's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Novacyt.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €9.99K | 0.02% |
| Total Liquid Assets | €9.99K | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Novacyt maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Novacyt Industry Peers by Asset Resilience Ratio
Compare Novacyt's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Medacta Group SA
SW:MOVE |
Medical Devices | 0.86% |
|
Double Medical Technology Inc
SHE:002901 |
Medical Devices | 12.59% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Sinocare Inc
SHE:300298 |
Medical Devices | 3.53% |
|
Xiangyu Medical Co. Ltd. A
SHG:688626 |
Medical Devices | 1.53% |
|
INKON Life Technology Co Ltd
SHE:300143 |
Medical Devices | 5.73% |
|
HOB Biotech Group Corp Ltd
SHG:688656 |
Medical Devices | 2.62% |
Annual Asset Resilience Ratio for Novacyt (2008–2025)
The table below shows the annual Asset Resilience Ratio data for Novacyt.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | €9.99K ≈ $11.68K |
€40.28 Million ≈ $47.09 Million |
-43.10pp |
| 2024-12-31 | 43.13% | €30.46 Million ≈ $35.61 Million |
€70.63 Million ≈ $82.58 Million |
+43.12pp |
| 2023-12-31 | 0.01% | €9.00K ≈ $10.52K |
€133.81 Million ≈ $156.44 Million |
-61.73pp |
| 2022-12-31 | 61.73% | €86.98 Million ≈ $101.69 Million |
€140.90 Million ≈ $164.73 Million |
+6.34pp |
| 2021-12-31 | 55.39% | €101.75 Million ≈ $118.96 Million |
€183.70 Million ≈ $214.76 Million |
+16.22pp |
| 2020-12-31 | 39.17% | €91.77 Million ≈ $107.29 Million |
€234.28 Million ≈ $273.89 Million |
+33.33pp |
| 2019-12-31 | 5.84% | €1.55 Million ≈ $1.81 Million |
€26.54 Million ≈ $31.03 Million |
+2.33pp |
| 2018-12-31 | 3.51% | €1.03 Million ≈ $1.20 Million |
€29.31 Million ≈ $34.27 Million |
+3.48pp |
| 2017-12-31 | 0.03% | €8.88K ≈ $10.38K |
€30.20 Million ≈ $35.31 Million |
0.00pp |
| 2016-12-31 | 0.03% | €8.52K ≈ $9.97K |
€25.95 Million ≈ $30.34 Million |
-6.77pp |
| 2015-12-31 | 6.80% | €858.99K ≈ $1.00 Million |
€12.62 Million ≈ $14.76 Million |
+6.77pp |
| 2014-12-31 | 0.04% | €7.81K ≈ $9.13K |
€20.77 Million ≈ $24.28 Million |
-31.41pp |
| 2013-12-31 | 31.45% | €837.46K ≈ $979.08K |
€2.66 Million ≈ $3.11 Million |
-10.05pp |
| 2012-12-31 | 41.50% | €1.37 Million ≈ $1.60 Million |
€3.30 Million ≈ $3.86 Million |
+38.74pp |
| 2011-12-31 | 2.76% | €34.80K ≈ $40.69K |
€1.26 Million ≈ $1.47 Million |
+2.24pp |
| 2010-12-31 | 0.53% | €10.00K ≈ $11.69K |
€1.90 Million ≈ $2.22 Million |
+0.00pp |
| 2009-12-31 | 0.52% | €10.00K ≈ $11.69K |
€1.92 Million ≈ $2.24 Million |
-14.29pp |
| 2008-12-31 | 14.81% | €244.00K ≈ $285.26K |
€1.65 Million ≈ $1.93 Million |
-- |
About Novacyt
Novacyt S.A., together with its subsidiaries, develops, manufactures, and commercializes a range of molecular assays and instrumentation to deliver workflows and services for human health, animal health, and environmental sectors. It operates through Yourgene Health and Primer Design segments. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive h… Read more